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Background: Target-controlled infusion (TCI) of propofol and remifentanil can provide satisfactory intubating 
conditions without a neuromuscular blocking agent. We compared the effect-site concentration of remifentanil 
required for intubation with the lightwand and the Macintosh laryngoscope during propofol TCI without a 
neuromuscular blocking agent in adult patients. 
Methods: Forty-nine patients were randomly assigned to the lightwand group (n = 25) or the direct laryngoscope 
group (n = 24). Anesthesia was induced by propofol TCI with an effect-site concentration of 5.4 μg/ml. Two minutes 
after start of propofol TCI, remifentanil was administered at the predetermined effect-site concentration. The effect-
site concentration of remifentanil was determined using Dixon’s up-and-down method (0.5 ng/ml as a step size). The 
first patient in each group was tested at 4.5 ng/ml of remifentanil. Tracheal intubation was performed 2 min after the 
start of remifentanil TCI. Acceptable intubation was defined as an excellent or good intubating conditions.
Results: Using a modified Dixon’s up and down method, the EC50 ± SD of remifentanil in the lightwand and 
laryngoscope groups was 4.75 ± 0.71 ng/ml and 5.08 ± 0.52 ng/ml, respectively; there was no statistically significant 
difference between the groups (P = 0.373).
Conclusions: The effect-site concentration of remifentanil for acceptable intubation with the lightwand and 
Macintosh laryngoscope in 50% of adults did not differ during propofol TCI without a neuromuscular blocking agent. 
(Korean J Anesthesiol 2011; 60: 393-397)
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Introduction
    As an alternative to direct laryngoscopy, the lightwand is an 
effective and safe intubation device. Theoretically, the lightwand 
technique may cause less adrenergic stimulation because the 
elevation of the epiglottis by the laryngoscope blade is not 
required. Previous studies have demonstrated that use of the 
lightwand for intubation of the tracheal tube causes a similar 
or lesser degree of a hemodynamic change when compared 
direct laryngoscopy [1-3]. Accordingly, the depth of anesthesia 
required to achieve ideal conditions for tracheal intubation 
using the lightwand may be different. Propofol and remifentanil 
have been shown to provide good intubating conditions without 
the use of neuromuscular blocking drugs [4,5]. To date, there 
have been no reports on the dose of remifentanil for acceptable 
tracheal intubation with the lightwand during propofol induc-
tion. Therefore, we compared the effect-site concentration of 
remifentanil concentration required for intubation with the 
lightwand and the Macintosh laryngoscope during propofol TCI 
without a neuromuscular blocking agent in adult patients. 
Materials and Methods
    This study was approved by the institutional review board, 
and written informed consent for the study was obtained 
from all patients. We enrolled ASA I or II patients, aged 18-60 
years, undergoing general anesthesia for nasal bone fracture 
surgery. Patients with a history of reactive airway disease, 
cardiovascular disease and suspected airway difficulty were 
excluded from the study. No premedication was administered 
prior to surgery. For drug injection, a 20-gauge cannula was 
inserted into the forearm or dorsum of the hand, and connected 
to a T-connector prior to arrival in the operating room. Upon 
entry to the operating room, all patients were monitored with 
an electrocardiogram, a pulse oximeter, and noninvasive blood 
pressure. Using a computer-generated randomization table, 
patients were randomly assigned to the lightwand group or 
the direct laryngoscope group. Following injection of 30 mg 
lidocaine, anesthesia was induced with propofol TCI with 
an effect-site concentration of 5.4 μg/ml. Two minutes after 
start of propofol TCI (i.e. when the predicted concentration of 
propofol between plasma and effect-site was reached a pseudo-
equilibrium state), remifentanil was administered through a 
TCI device at the predetermined effect-site concentration. A 
commercially available two-channel TCI pump (Orchestra
Ⓡ, 
Fresenius Vial, Brezins, France) was used for effect-site TCI of 
propofol and remifentanil. The pharmacokinetic models used 
for calculation of target effect-site concentrations for propofol 
and remifentanil were described previously by Marsh and 
colleagues [6] and Minto and colleagues [7], respectively. The ke0 
value used for propofol was 1.21/min [8]. Infusions of propofol 
and remifentanil were prepared in 50 ml syringes using 2% 
propofol and 2 mg of remifentanil (diluted with normal saline to 
make a 40 μg/ml solution). Tracheal intubation was performed 
2 min after the start of remifentanil TCI (when the predicted 
concentration of remifentanil between plasma and effect-site 
was reached a pseudo-equilibrium state). Tracheal intubations 
were carried out using either a Macintosh laryngoscope or 
a lightwand (Surch-Lite
TM, Aaron Medical Industries, St. 
Petersburg, FL). Endotracheal tubes with an internal diameter 
of 7.0 mm were used for female patients and tubes with an 
internal diameter of 8.0 mm were used for male patients.
    The effect-site concentration of remifentanil for each patient 
was determined by the response of the previously tested patient 
using a modified Dixon’s up-and-down method (0.5 ng/
ml as a step size) [9]. The first patient was tested at an effect-
site concentration of remifentanil 4.5 ng/ml. This was a target 
concentration close to the predicted remifentanil concentration 
at which there was a 50% probability of acceptable tracheal 
intubation (EC50) using a Macintosh laryngoscope [10]. If 
intubation was unacceptable, the target effect-site concentration 
of remifentanil for the next patient was increased by 0.5 ng/ml. 
If acceptable, it was then decreased by 0.5 ng/ml. Intubating 
conditions were evaluated according to a scoring system des-
cribed by Viby-Mogensen [11] and are summarized in Table 1. 
However, vocal cord variables were excluded in the lightwand 
group. Acceptable intubation was defined as excellent or good 
intubating conditions. The anesthesiologist who performed 
the intubations and who assessed the intubating conditions 
was unaware of the effect-site concentration of remifentanil. 
If intubation failed due to strong movement by the patient, 
inadequate jaw relaxation, or closed vocal cords, target 
concentration of propofol and remifentanil increased to 6 to 8 
μg/ml and 6 to 8 ng/ml, respectively. Thereafter, intubation was 
attempted. Clinically significant hypotension and bradycardia 
were defined as a mean arterial pressure (MAP) of < 55 
mmHg and a heart rate (HR) of < 45 beats/min, respectively. 
Table 1.  Assessment of Intubation Conditions
Variables
Intubating conditions
Acceptable Unacceptable 
Excellent Good  Poor
Ease of laryngoscopy
  or jaw relaxation
Vocal cord position
Vocal cord movement
Airway reaction (coughing)
Movement of the limbs
Easy
Abducted
None
None
None
Fair
Intermediate
Moving
Diaphragm
Slight
Difficult
Closed
Closing
Sustained
Vigorous
Excellent: all criteria are excellent. Good: all criteria are either excel-
lent or good. Poor: presence of a single criterion listed under ‘Poor’ .395 www.ekja.org
Korean J Anesthesiol Kim, et al.
These conditions were treated with atropine or ephedrine 
where appropriate. Laryngospasm was treated with increased 
propofol concentration and 0.3 mg/kg of rocuronium. MAP, HR, 
and SpO2 were recorded at anesthetic induction, 2 min after 
propofol infusion, before and 1 min after intubation. Time to 
loss of consciousness (LOC) and time to tracheal intubation 
were also measured. Time to intubation was defined as the 
interval between opening of the mouth and inflation of the 
endotracheal cuff.
    This study ended when data from six independent pairs of 
patients with acceptable/unacceptable intubating conditions 
were collected in each group. Statistical analyses were perfor-
med using SPSS 13.0 for windows (SPSS Inc, Chicago, IL, 
USA). Data are expressed as mean ± SD or number of patients. 
The EC50 of remifentanil which enabled acceptable tracheal 
intubation was determined by calculation of the average of 
the midpoint dose of all independent pairs of patients after six 
crossover points were obtained in each group. 
    Patient characteristics and induction profiles were compared 
using a Student’s t-test. Changes in hemodynamic data between 
the groups were compared by repeated measures ANOVA. 
Changes between time points within the group were analyzed 
using univariate analysis of variance (ANOVA) followed by least 
significant difference (LSD) post hoc test. A P value of < 0.05 
was considered significant.
Results
    Forty-nine patients were enrolled in this study. No significant 
differences in patient characteristics were observed between the 
two groups (Table 2). However, intubation time was significantly 
longer in the lightwand group than in the laryngoscope group 
(Table 2). Intubating conditions were good or excellent (i.e. 
acceptable intubation) in 12/25 patients in the lightwand 
group and 12/24 patients in the laryngoscope group (Table 3). 
Table 4 lists hemodynamic data from patients with acceptable 
intubation during induction of anesthesia. The differences 
in MAP and HR over time were not statistically significant 
between the groups (P = 0.510, 0.852, respectively). Compared 
to the baseline value in both groups, MAP showed a significant 
decrease after anesthetic induction. Compared to the baseline 
value in both groups, HR showed no significant change during 
the induction of anesthesia. Fig. 1 shows the sequences of 
effect-site concentration of remifentanil for acceptable and 
unacceptable tracheal intubation in the two groups. Using 
Dixon’s up and down method, the EC50 ± SD of remifentanil 
in the lightwand and laryngoscope groups was 4.75 ± 0.71 ng/
ml and 5.08 ± 0.52 ng/ml, respectively; there was no significant 
Table 4.  Mean Arterial Pressure (MAP) and Heart Rate (HR) during Anesthesia Induction in Acceptable Intubation Patients
Group T0 T1 T3 T4 P value
MAP (mmHg)
    Lightwand
    Laryngoscopy
HR (beats/min)
    Lightwand
    Laryngoscopy
93.9 ± 10.9
94.2 ± 12.7
68.8 ± 15.5
72.0 ± 10.2
77.7 ± 8.5*
80.8 ±11.8* 
66.5 ± 9.8
69.9 ± 10.9 
72.6 ± 10.5*
76.4 ± 12.6*
62.7 ± 7.7
63.7 ± 8.1
75.0 ± 12.7*
78.3 ± 13.1*
70.1 ± 13.2
65.3 ± 12.0
0.510
0.852
Values represent mean ± SD.  T0: baseline, T1: 2 min after propofol infusion, T3: before intubation. T4: 1 min after intubation.  There were no 
significant differences in MAP and HR over time between the groups. *P < 0.05 compared with baseline value.
Table 2.  Patient Characteristics 
Lightwand
 (n = 25)
Laryngosocpy 
(n = 24)
P value
Sex (M/F)
Age (yr)
Weight (kg)
Height (cm)
ASA class (I/II)
Time to LOC (s)
Time to intubation (s)
Total anesthesia time (min)
21/4
33.3 ± 10.1
66.0 ± 9.8
170.8 ± 7.7
24/1
67.2 ± 25.0
28.8 ± 7.7
28.0 ± 3.8
22/2
31.3 ± 10.0
68.0 ± 12.8
173.9 ± 8.5
21/3
59.8 ± 19.8
24.0 ± 6.7*
25.8 ± 3.8
0.413
0.484
0.546
0.205
0.277
0.258
0.025
0.053
Values represent mean ± SD or number of patients.  LOC: loss of con-
sciousness.  *P < 0.05 compared with the lightwand group.
Table 3.  Intubation Conditions
Lightwand
 (n = 25)
Laryngosocpy 
(n = 24)
Acceptable
    Total
    Excellent
    Good
Unacceptable
    Total
    Succeeded
    Failed
Cause of failure
    Difficulty of jaw relaxation
    Closed vocal cord
    Airway reaction (coughing)
    Vigorous limb movements
12
  2
10
13
13
  0
  2
NA
12
  5
12
  3
  9
12
10
  2
  3
  1
  7
  3
Values represent the number of patients.  There were no significant 
differences between the groups.396 www.ekja.org
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difference between the groups (P = 0.373). There were also no 
adverse respiratory events, such as laryngospasm, and SpO2 
remained above 90% in all patients. None of the acceptable 
intubation patients suffered clinically significant bradycardia or 
hypotension. 
Discussion
    This study demonstrated that the effect-site concentration 
of remifentanil for acceptable intubation conditions using the 
lightwand and the Macintosh laryngoscope was 4.75 ± 0.71 ng/
ml and 5.08 ± 0.52 ng/ml, respectively, in 50% of adults during 
propofol TCI at an effect-site concentration of 5.4 μg/ml without 
a neuromuscular blocking agent; there was no statistical 
difference between the groups. 
    The lightwand technique does not require that the mouth is 
wide open or that the epiglottis is elevated, or brought forward 
and lifted upward by the laryngoscope. In comparison with the 
use of the laryngoscope, the lightwand, which does not require 
a laryngoscope to elevate the epiglottis, should attenuate the 
airway reflexes. We assumed that intubation with the lightwand 
may be less stimulating, and that the dose of remifentanil 
required for lightwand intubation without neuromuscular 
blockade might be decreased. However, our results have 
shown that the EC50 of remifentanil for the lightwand and 
the laryngoscopic intubation was 4.75 ± 0.71 ng/ml and 5.08 
± 0.52 ng/ml, respectively, during propofol TCI, indicating 
there was no strong evidence that the target concentrations 
of remifentanil for clinically acceptable intubation conditions 
differed based on the techniques used for intubation. In this 
study, the overall assessment of all variables suggest that 
coughing might be the main reason for failed intubation. 
This result implies that tracheal stimulus, and not stimuli to 
the oropharyngeal structures, is the primary cause of a stress 
response during tracheal intubation. In addition, a previous 
study reported that target remifentanil concentrations required 
for adequate intubating conditions did not differ between the 
Macintosh laryngoscope and the Glidescope [10].
    In our study, there were no differences in hemodynamic 
changes between use of the lightwand technique and Macintosh 
laryngoscopy after tracheal intubation. These results are 
consistent with those of previous studies, which revealed similar 
hemodynamic responses between the techniques [3,12,13]. 
Hirabayashi et al. [3] reported that maximum MAP changes 
and HR changes were similar between the lightwand technique 
and direct laryngoscopy during and after tracheal intubation. 
Moreover, Takahashi et al. [12] demonstrated that the magni-
tude of hemodynamic changes associated with tracheal intu-
bation with the lightwand (Trachlight) is almost the same 
as that which occurs with the direct laryngoscope. And they 
suggested hemodynamic changes are likely to occur because 
of direct tracheal irritation rather than direct stimulation of 
the larynx. Lastly, Montes et al. [13] have also shown that the 
lightwand technique does not reduce the hemodynamic res-
ponse compared to standard direct-vision laryngoscopic intu-
bation in patients with coronary artery disease. In contrast, 
Nishigawa et al. [1] reported that lightwand intubation produces 
a smaller increase in systolic blood pressure after tracheal 
intubation than with Macintosh laryngoscopic intubation in 
normotensive patients; however, in hypertensive patients, 
there were no differences in hemodynamic changes between 
the two techniques. Another comparative study showed that 
Fig. 1. Responses of 25 (lightwand, A) and 24 (laryngoscope, B) consecutive patients where tracheal intubation was attempted and the effect-
site concentration of remifentanil. The EC50 of remifentanil in the lightwand group and the laryngoscope group was 4.75 ± 0.71 ng/ml and 5.08 
± 0.52 ng/ml, respectively.397 www.ekja.org
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the lightwand attenuated the hemodynamic stress response 
to tracheal intubation when compared with the Macintosh 
laryngoscope in hypertensive, but not in normotensive patients 
[2]. Collectively, these conflicting results are likely related to 
differences in intubation techniques, in anesthetic regimen, 
and the method of recording hemodynamic variables. 
    Propofol TCI and adjuvant remifentanil have been shown to 
provide acceptable intubation conditions for tracheal intubation 
in adults without the use of a neuromuscular blocking agent 
[10,14]. Ithnin et al. [10] reported that the EC50 of remifentanil 
required for optimal tracheal intubating conditions was 4.41 
ng/ml when the propofol TCI effect-site concentration was 
3.0 μg/ml. These results were comparable to findings from our 
study. The EC50 of remifentanil in our study using Macintosh 
laryngoscopy intubation was 5.08 ± 0.52 ng/ml during propofol 
TCI at an effect-site concentration of 5.4 μg/ml. Since Smith et 
al. [15] have reported that the propofol blood concentration at 
which 95% of patients did not respond to verbal command was 
5.4 μg/ml, we selected this concentration of propofol for the 
induction of anesthesia. When propofol is administrated at a 
target effect-site concentration of 5.4 μg/ml using the integrated 
Marsh model, a pseudo-equilibrium state between plasma and 
effect-site is reached approximately 1.6 min after the start of TCI. 
    Tracheal intubation without neuromuscular blocking drugs 
may be used in cases where tracheal intubation is necessary 
but prolonged muscle relaxation is not, such as in short surgical 
procedures. We enrolled patients with nasal bone fractures, 
and total anesthetic time in our study was less than 30 min. 
However, use of neuromuscular blocking drugs for tracheal 
intubation diminishes the incidence of adverse postoperative 
upper airway symptoms, results in better intubation conditions, 
and reduces the rate of adverse hemodynamic events [16]. In 
addition, avoidance of neuromuscular blocking drugs may 
increase the risk of difficult tracheal intubation [17]. Therefore, 
a more careful approach is needed for neuromuscular blocking 
agent-free intubation.
    In conclusion, the predicted effect-site concentration of remi-
fentanil for acceptable intubation with the lightwand in 50% of 
adults was 4.75 ng/ml, when a propofol TCI of 5.4 μg/ml was 
used without a neuromuscular blocking agent. Concentrations 
of remifentanil for acceptable intubation with the lightwand 
and direct laryngoscopy did not differ. 
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